You are here

  • Home
  • Archive
  • Volume 72, Issue 2
  • Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

Article info

Article menu
Download PDFPDF
Review
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective

Authors

  • Fabien B Vincent Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Eric F Morand Centre for Inflammatory Diseases, Southern Clinical School, Monash University, Monash Medical Centre, Clayton, Victoria, Australia PubMed articlesGoogle scholar articles
  • Kim Murphy Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Fabienne Mackay Department of Immunology, Monash University, Central Clinical School, Alfred Medical Research and Education Precinct (AMREP), Melbourne, Victoria, Australia PubMed articlesGoogle scholar articles
  • Xavier Mariette Department of Rheumatology, Université Paris-Sud, AP-HP, Groupe Hospitalier Universitaire Paris-Sud, INSERM U1012, 78 rue du Général Leclerc, Le Kremlin Bicêtre, France PubMed articlesGoogle scholar articles
  • Christian Marcelli Department of Rheumatology, University Hospital Centre of Caen, avenue de la Côte de Nacre, Caen, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Fabien B Vincent, B lymphocyte, BAFF and Autoimmunity Laboratory, Department of Immunology, Monash University, Level 2, AMREP Building, 89 Commercial Road, Melbourne, Victoria 3004, Australia; vincent.fabien{at}gmail.com
View Full Text

Citation

Vincent FB, Morand EF, Murphy K, et al
Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective
Annals of the Rheumatic Diseases 2013;72:165-178.

Publication history

  • Accepted October 28, 2012
  • First published November 24, 2012.
Online issue publication 
April 13, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions